Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Publication/Presentation Date

11-2019

Volume

134

Issue

1

First Page

5318

Last Page

5318

Disciplines

Medicine and Health Sciences

Department(s)

Hematology-Medical Oncology Division

Document Type

Article

Share

COinS